1265 related articles for article (PubMed ID: 17996658)
1. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Int J Clin Pract; 2007 Oct; 61(10):1634-42. PubMed ID: 17877650
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
Torimoto K; Okada Y; Mori H; Hajime M; Tanaka K; Kurozumi A; Narisawa M; Yamamoto S; Arao T; Matsuoka H; Inokuchi N; Tanaka Y
Lipids Health Dis; 2013 Sep; 12():137. PubMed ID: 24053480
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Yamazaki D; Ishida M; Watanabe H; Nobori K; Oguma Y; Terata Y; Koyama T; Iino K; Kosaka T; Ito H
Lipids Health Dis; 2013 Feb; 12():9. PubMed ID: 23374898
[TBL] [Abstract][Full Text] [Related]
6. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Khokhar SA; Farooq Ur Rehman RM; Masood S
J Pak Med Assoc; 2022 Nov; 72(11):2288-2290. PubMed ID: 37013304
[TBL] [Abstract][Full Text] [Related]
8. Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Dautović E; Rustemović-Čorbić M; Srabović N; Softić A; Smajlović A; Husejnović MŠ; Hatkić A; Halilčević D
Adv Med Sci; 2023 Sep; 68(2):258-264. PubMed ID: 37478516
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin for lowering lipids.
Adams SP; Alaeiilkhchi N; Tasnim S; Wright JM
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD013673. PubMed ID: 37721222
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of statins in managing cardiovascular risk.
Kapur NK; Musunuru K
Vasc Health Risk Manag; 2008; 4(2):341-53. PubMed ID: 18561510
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).
Binbrek AS; Elis A; Al-Zaibag M; Eha J; Keber I; Cuevas AM; Mukherjee S; Miller TR;
Curr Ther Res Clin Exp; 2006 Jan; 67(1):21-43. PubMed ID: 24936119
[TBL] [Abstract][Full Text] [Related]
12. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial.
Ju SH; Lim JY; Song M; Kim JM; Kang YE; Yi HS; Joung KH; Lee JH; Kim HJ; Ku BJ
Front Endocrinol (Lausanne); 2024; 15():1336357. PubMed ID: 38586464
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Yu JM; Chen WM; Shia BC; Wu SY
Eur J Clin Pharmacol; 2023 May; 79(5):687-700. PubMed ID: 37010535
[TBL] [Abstract][Full Text] [Related]
15. Reducing morbidity and mortality in high risk patients with statins.
Singh V; Deedwania P
Vasc Health Risk Manag; 2009; 5(2):495-507. PubMed ID: 19554090
[TBL] [Abstract][Full Text] [Related]
16. Statin wars following coronary revascularization--evidence-based clinical practice?
Brophy JM; Costa V
Can J Cardiol; 2006 Jan; 22(1):54-8. PubMed ID: 16450018
[TBL] [Abstract][Full Text] [Related]
17. Statin use and the risk of Clostridium difficile in academic medical centres.
Motzkus-Feagans CA; Pakyz A; Polk R; Gambassi G; Lapane KL
Gut; 2012 Nov; 61(11):1538-42. PubMed ID: 22442166
[TBL] [Abstract][Full Text] [Related]
18. To study impact of treatment with Rosuvastatin versus Atorvastatin on 25 hydroxy Vitamin D concentrations among adult Indian men- a randomized control trial.
Patwardhan VG; Mughal ZM; Padidela R; Chiplonkar SA; Khadilkar VV; Khadilkar AV
Indian J Pharmacol; 2020; 52(5):365-371. PubMed ID: 33283767
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of alternate day versus daily dosing of rosuvastatin.
Dulay D; LaHaye SA; Lahey KA; Day AG
Can J Cardiol; 2009 Feb; 25(2):e28-31. PubMed ID: 19214297
[TBL] [Abstract][Full Text] [Related]
20. Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy.
Lynch JT; Cooke CE; Rosen J; Gandhi S; Bullano MF
Am Health Drug Benefits; 2010 Sep; 3(5):340-9. PubMed ID: 25126327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
